Steven P. Coen - 16 Jan 2026 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Financial Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol
DNA
Transactions as of
16 Jan 2026
Net transactions value
-$8,667
Form type
4
Filing time
22 Jan 2026, 16:12:16 UTC
Previous filing
16 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coen Steven P. Chief Financial Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON /s/ Karen Tepichin, Attorney-in-Fact 22 Jan 2026 0001977441

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +587 +7.8% 8,075 16 Jan 2026 Direct F1
transaction DNA Class A Common Stock Options Exercise +156 +1.9% 8,231 16 Jan 2026 Direct F1
transaction DNA Class A Common Stock Options Exercise +1,062 +13% 9,293 16 Jan 2026 Direct F1
transaction DNA Class A Common Stock Sale $8,667 -972 -10% $8.92 8,321 20 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -587 -5.9% 9,405 16 Jan 2026 Class A Common Stock 587 Direct F1, F3
transaction DNA Restricted Stock Units Options Exercise -156 -3.7% 4,067 16 Jan 2026 Class A Common Stock 156 Direct F1, F4
transaction DNA Restricted Stock Units Options Exercise -1,062 -100% 0 16 Jan 2026 Class A Common Stock 1,062 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3 The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
F4 The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
F5 The RSUs vest as follows: 25% vested on April 16, 2025; 25% vested on July 16, 2025; 25% vested on October 16, 2025; and 25% vested on January 16, 2026.

Remarks:

Chief Financial Officer